Showing results (1-10 of 156) with videos related to
Sort By:
Pageof 16
Expert Opinion on Drug Safety|September 12, 2015
The clinical safety of ibrutinib in chronic lymphocytic leukemiaStefano MolicaBMC Medicine|August 17, 2017
Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017Stefano MolicaExpert Review of Hematology|November 17, 2025
Beyond progression-free survival (PFS): time to next treatment (TTNT) as a patient-centered metric of clinical benefit in chronic lymphocytic leukemia (CLL)Stefano MolicaExpert Review of Hematology|March 17, 2026
Frailty and chronic lymphocytic leukemia: navigating challenges to improve outcomesStefano MolicaInternational Journal of Hematologic Oncology|December 9, 2020
Venetoclax: a real game changer in treatment of chronic lymphocytic leukemiaStefano MolicaLeukemia & Lymphoma|September 13, 2006
Sex differences in incidence and outcome of chronic lymphocytic leukemia patientsStefano MolicaExpert Review of Hematology|May 24, 2018
The future of chronic lymphocytic leukemia: potential directions from ASH 2017Stefano MolicaLeukemia & Lymphoma|December 29, 2004
Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapiesStefano MolicaMed (New York, N.Y.)|February 14, 2026
CLL17: Fixed-duration paradigms match continuous ibrutinib in frontline chronic lymphocytic leukemiaStefano MolicaPageof 16